Organ-conserving operations in breast cancer: indication, contraindication and recurens


  • Cojocaru Ana Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” Catedra de Oncologie
  • Sveţ Veronica Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” Catedra de Oncologie



mammary gland, organ surgery, sectoral resection, regional lymphadenectomy, recurrence


Organ-сonserving operations in breast cancer include performing extended sectoral resections with regional lymphadenectomy. In the case of these interventions, immediate histological examination of the safe margins and subareolar area will be mandatory. Overly economical tactics are associated with the risk of breast cancer recurrence. Organ-preserving breast cancer surgeries, supplemented with radiation therapy, are a safe alternative to mastectomy with the correct selection of patients with early forms

Author Biographies

Cojocaru Ana, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” Catedra de Oncologie

studentă, coordonator

Sveţ Veronica, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” Catedra de Oncologie

asist. univ


International Agency for Research on Cancer. GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018. [accesat la 2.08.2019].

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review,1975–2016. Bethesda, MD: Na- tional Cancer Institute. 2018: 126-142.

Cancer Registru Național, IMSP Institutul Onco- logic, [accesat la 2.08.2020].

Protocolul Clinic Național PCN-102 “Cancerul glandei mamare” din 23.01.2020.

Krop I, Ismaila N,Andre F et al. Use of biomark- ers to guide decisions on adjuvant systemic therapy for women with early‐stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline focused update.J ClinmOncol 2019;35:2838–2847.

Kuerer HM, Smith BD, Chavez-MacGregor M, et al. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017;8(14):2653-2662

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) – Breast Cancer. Version 3.2018 — October 25, 2018.

Senkus E, Kyriakides S, Ohno S, Penault-Llor- ca F, Poortmans P, Rutgers E,Zackrisson S, Cardoso F; ESMO Guidelines Committee. Primary breast cancer:ES- MO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30.

Gaurav A, Gupta V, et al. Practical consensus recommendation for Paget’s disease in breast cancer. Soth Asian J Cancer 2018, 7(2), 83-86.

Foster RS Jr. The biologic and clinical signifi- cance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am.;5:79–104, 2019.

Veronesi U, Paganelli G, Viale G, et al. Sentinel Lymph Node Biopsy and Axillary Dissection in Breast Cancer: Results in a Large Series. J Natl Cancer Inst. 2019;91:368–73.

Botnariuc N. Factorii de pronostic în tratamentul cancerului glandei mamare în stadiul I. Teză de doctor în ştiinţe medicale. 2010; 112.

Chiaburu S. Particularităţile de diagnostic, tratament şi pronostic ale carcinomului neinvaziv al glandei mamare. Teză de doctor în ştiinţe medicale. 2011; 123.

Sofroni L. Cancerul glandei mamare- maladia întregii civilizaţii. Buletinul Academiei de Ştiinţe a Moldo- vei. 2018; 2-3(59-60): 132-137.

Chiaburu S. Aprecierea tacticii de tratament in- traoperator al carcinomului neinvaziv mamar în depen- dent de datele clinice, imagistice şi morfologice. Buletinul Academiei de Ştiinţe a Moldovei. 2013; 4(40): 73-76.

American Cancer Society. Breast Cancer. Dispo- nibil la: [ac- cesat la 11.06.2020]





Research Article